Acetazolamide for patients with acute decompensated heart failure with volume overload

Xavier Rossello 1,2,3*, Venu Menon 4, and Pascal Vranckx 5,6

1Cardiology Department, Institut d’Investigació Sanitària Illes Balears (IdISBa), Hospital Universitari Son Espases, 07120 Palma, Spain; 2Translational Laboratory for Cardiovascular Imaging and Therapy, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; 3Facultad de Medicina, Universitat de les Illes Balears (UIB), 07122 Palma, Spain; 4Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; 5Department of Cardiology and Critical Care Medicine, Hartencentrum Hasselt, Jessa Ziekenhuis, 3500 Hasselt, Belgium; and 6Faculty of Medicine and Life Sciences, Hasselt University, 3500 Hasselt, Belgium

Online publish-ahead-of-print 12 September 2022

The Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial showed that the addition of acetazolamide to loop diuretic therapy in patients with acute decompensated heart failure (ADHF) in a greater incidence of successful decongestion.1,2

Description
The goal of the trial was to evaluate whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal tubular sodium reabsorption, can improve the efficiency of loop diuretics, potentially leading to more and faster decongestion in patients with ADHF with volume overload.3

Study design
• Randomization
• Parallel
• Double-blind
• Placebo-controlled
• Multicentre (nationwide)
• Outcome based on a congestion score (evaluated by a single observer)

Patients with ADHF, clinical signs of volume overload (i.e. oedema, pleural effusion, or ascites), and an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of more than 1000 pg per milliliter or a B-type natriuretic peptide (BNP) level of more than 250 pg per milliliter were randomized to receive either intravenous acetazolamide (500 mg once daily) (n = 259) or placebo (n = 260) added to standardized intravenous loop diuretics (at a dose equivalent to twice the oral maintenance dose). Randomization was stratified according to the left ventricular ejection fraction (≤40% or >40%) and trial site.

At randomization, oral loop diuretics were stopped, and the patient received an intravenous loop diuretic at double the oral maintenance dose, administered as a single bolus immediately after randomization and split into two doses (separated by ≥6 h) on each of the next 2 days. The bolus of acetazolamide or matching placebo was administered simultaneously with the first dose of loop diuretics each day.

All patients received the same maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 administered over 24 h until the end of the study treatment phase. Daily oral intake of fluids and sodium was restricted to 1500 mL and 1.5 g, respectively.

Patient population
• Total number of trial participants: 519 subjects
• Duration of follow-up: 3 months
• Mean patient age: 78 years
• Percentage female: 37%

Other salient features/characteristics
• Left ventricular ejection fraction ≤40%: 43%
• Median congestion score at baseline [interquartile range (IQR)]: 4 (3–6)
• Median NT-proBNP level (IQR): 6173 (3068–10 896) pg per millilitre
• Median home maintenance dose of furosemide equivalent (IQR): 60 (40–100) mg

Inclusion criteria
Patients with an elective or emergency hospital admission and clinical diagnosis of acute heart failure were eligible for the trial if:

• ≥1 clinical sign of volume overload (i.e. oedema, ascites confirmed by abdominal ultrasound, or pleural effusion confirmed by a chest X-ray or chest ultrasound).
• Maintenance therapy with oral loop diuretics at a dose of ≥1 mg bumetanide or ≥40 mg furosemide or ≥20 mg torsemide for ≥1 month.
• Plasma NT-proBNP level > 1000 pg/mL or BNP level > 250 ng/mL at screening.

* Corresponding author. Email: fjrossello@ssib.es

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
**Exclusion criteria**

- Systolic blood pressure < 90 mmHg or mean arterial pressure < 65 mmHg.
- Expected use of intravenous inotropes, vasopressors, or sodium nitroprusside at any time point during the study. Nitroprusside only if systolic blood pressure is > 140 mmHg.
- Estimated glomerular filtration rate < 20 mL/min/1.73 m².
- Treatment with intravenous loop diuretics > 2 mg bumetanide or an equivalence of another loop diuretic during the index hospitalization and prior to randomization.
- Maintenance treatment with acetazolamide or sodium–glucose co-transporter-2 (SGLT2) inhibitors.
- Use of any non-protocol defined diuretic agent except for mineralocorticoid receptor antagonists.
- Concurrent diagnosis of an acute coronary syndrome defined as typical chest pain in addition to a troponin rise above the 99th percentile and/or electrocardiographic changes suggestive of cardiovascular ischaemia.

**Principal findings**

The primary outcome of successful decongestion (no more than trace oedema, no residual pleural effusion, and no residual ascites within 3 days after randomization without an indication for escalation of decongestion therapy) occurred in 108 of 256 patients (42.2%) in the acetazolamide group and in 79 of 259 (30.5%) in the placebo group (risk ratio, 1.46; 95% confidence interval [CI], 1.17 to 1.82; P < .001).³ The primary endpoint of successful decongestion could not be assessed in four patients.

The effect of acetazolamide on the primary endpoint was generally consistent across prespecified subgroups, although the patients who were receiving a higher maintenance dose of loop diuretics appeared to have less benefit than those who were receiving a lower maintenance dose.¹ The key secondary endpoint of death from any cause or rehospitalization for heart failure during 3 months of follow-up occurred in 76 of 256 patients (29.7%) in the acetazolamide group and in 72 of 259 patients (27.8%) in the placebo group (hazard ratio, 1.07; 95% CI, 0.78–1.48). The duration of the index hospital admission (i.e., the number of days from randomization until the date of discharge) was a geometric mean of 8.8 days (95% CI, 8.0–9.5) in the acetazolamide group and 9.9 days (95% CI, 9.1–10.8) in the placebo group.¹

**Interpretation**

Expansion of extracellular fluid volume is critical to the pathophysiology of heart failure.² Increased extracellular fluid leads to elevated intracardiac filling pressures, resulting in a constellation of signs and symptoms of ADHF referred to as congestion. The evidence generated by the ADVOR trial confirms that the addition of acetazolamide to loop diuretics, both acetazolamide and SGLT2 inhibitors has the mechanism of action in the proximal renal tubule, making harder to predict a potential cumulative effect.

**Acknowledgements**

None declared.

**Funding**

None declared.

**Conflict of interest:** None declared.

**Data availability**

There are no original data in this editorial.

**References**

1. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierickx R, Bloisard P, Trosfontaines P, Dethoo D, Smolders W, Bruckers L, Drooghe W, Ter Maaten M, Damman K, Lassu J, Mebazaa A, Filipatos G, Ruschitzka F, Dupont M. ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022. doi:10.1056/NEJMoa2203094

2. Felker GM. New decongestion strategies in an evolving heart failure landscape. N Engl J Med 2022. doi:10.1056/NEJMr2209997

3. Mullens W, Verbrugge FH, Nijst P, Martens E, Tartaglia K, Theunissen E, Bruckers L, Drooghe W, Trosfontaines P, Damman K, Lassu J, Mebazaa A, Filipatos G, Ruschitzka F, Dupont M. Rationale and design of the ADVOR (acetazolamide in decompensated heart failure with volume overload) trial. Eur J Heart Fail 2018;20:1591–1600.

4. Rossello X, Bueno H, Gil V, Jacob J, Martin-Sánchez FJ, Llorens P, Puente FH, Alquézar-Arbé E, Espinosa B, Ropero-Robinb S, Müller CE, Mebazaa A, Magnoni AP, Poccioc S, Chiocchio O, Miró O. ICA-SEMS Research Group. Synergistic impact of systolic blood pressure and perfusion status on mortality in acute heart failure. Circ Heart Fail 2021;14:312–323.

5. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouselle JL, Olli EO, Amstrong KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfouri AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797–805.

6. McDonagh TA, Metra M, Adamo M, Gardner RS, Van Craenenbroeck E, Vandekerckhove H, Hofkens PJ, Goossens K, Pouleur A-C, De Geest A, Börger MA, Butds W, Cîkes M, Damman K, Delgado V, Dendale P, Dilsaver P, Drexel H, Ezhokovitz F, Fahl C, Fauchar L, Filipatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Jung B, Janssens S, Jessup M, Kornadí A, Kotecha D, Lambiris E, Lancellotti P, Landmesser U, Legrand C, Lewis BS, Leya F, Lianí HK, Ludh LH, Mancini D, Maspal J, Milicic D, Mueller C, Nef H, Nielsen JC, Neubeck L, Noutias M, Petersen SE, Scirica BM, Sionkowska P, Prescott E, Rakheva A, Richter DJ, Schlyakhto E, Seferovic P, Senni M, Sigs M, Sousa-Uva M, Tocochi CG, Touyz RM, Tschope C, Wahlenberger J, Adamo M, Baumbach A, Böhm M, Burni H, Butler J, Čelutkienė J, Chiocchio O, Cîlesan JG, Coats AJ, Crespo-Leiro MP, Damman K, de Boer RA, Abdelhamid M, Aboyans V, Andromopoulos S, Arker SD, Arbelo E, Astegiano R, Bauersachs J, Bayes-Genis A, Bolt MA, Butds W, Cîkes M, Damman K, Delgado V, Dendale P, Dilsaver P, Drexel H, Ezhokovitz F, Fahl C, Fauchar L, Filipatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Jung B, Janssens S, Jessup M, Kornadí A, Kotecha D, Lambiris E, Lancellotti P, Landmesser U, Legrand C, Lewis BS, Leya F, Lianí HK, Ludh LH, Mancini D, Maspal J, Milicic D, Mueller C, Nef H, Nielsen JC, Neubeck L, Noutias M, Petersen SE, Scirica BM, Sionkowska P, Prescott E, Rakheva A, Richter DJ, Schlyakhto E, Seferovic P, Senni M, Sigs M, Sousa-Uva M, Tocochi CG, Touyz RM, Tschope C, Wahlenberger J, Adamo M, Baumbach A, Böhm M, Burni H, Butler J, Čelutkienė J, Chiocchio O, Cîlesan JG, Coats AJ, Crespo-Leiro MP, Damman K, de Boer RA, Abdelhamid M, Aboyans V, Andromopoulos S, Arker SD, Arbelo E, Astegiano R, Bauersachs J, Bayes-Genis A, Bolt MA, Butds W, Cîkes M, Damman K, Delgado V, Dendale P, Dilsaver P, Drexel H, Ezhokovitz F, Fahl C, Fauchar L, Filipatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Jung B, Janssens S, Jessup M, Kornadí A, Kotecha D, Lambiris E, Lancellotti P, Landmesser U, Legrand C, Lewis BS, Leya F, Lianí HK, Ludh LH, Mancini D, Maspal J, Milicic D, Mueller C, Nef H, Nielsen JC, Neubeck L, Noutias M, Petersen SE, Scirica BM, Sionkowska P, Prescott E, Rakheva A, Richter DJ, Schlyakhto E, Seferovic P, Senni M, Sigs M, Sousa-Uva M, Tocochi CG, Touyz RM, Tschope C, Wahlenberger J, Adamo M, Baumbach A, Böhm M, Burni H, Butler J, Čelutkienė J, Chiocchio O, Cîlesan JG, Coats AJ, Crespo-Leiro MP, Damman K, de Boer RA, Abdelhamid M, Aboyans V, Andromopoulos S, Arker SD, Arbelo E, Astegiano R, Bauersachs J, Bayes-Genis A, Bolt MA, Butds W, Cîkes M, Damman K, Delgado V, Dendale P, Dilsaver P, Drexel H, Ezhokovitz F, Fahl C, Fauchar L, Filipatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Jung B, Janssens S, Jessup M, Kornadí A, Kotecha D, Lambiris E, Lancellotti P, Landmesser U, Legrand C, Lewis BS, Leya F, Lianí HK, Ludh LH, Mancini D, Maspal J, Milicic D, Mueller C, Nef H, Nielsen JC, Neubeck L, Noutias M, Petersen SE, Scirica BM, Sionkowska P, Prescotti